Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women With HIV in the United States

Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.

Start Date15 Oct 2026

Sponsor / Collaborator

International Maternal Pediatric Adolescent AIDS Clinical Trials Network

[+2]

NCT07688369

/ Not yet recruitingPhase 1

A Phase 1, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).

Start Date01 Jul 2026

Sponsor / Collaborator

Serum Institute of India Pvt Ltd.

NCT07650916

/ RecruitingPhase 3

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART

This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).

Start Date25 Jun 2026

Sponsor / Collaborator

ViiV Healthcare Ltd.

100 Clinical Results associated with Rilpivirine Hydrochloride

100 Translational Medicine associated with Rilpivirine Hydrochloride

100 Patents (Medical) associated with Rilpivirine Hydrochloride

1,850

Literatures (Medical) associated with Rilpivirine Hydrochloride

31 Dec 2026·HIV Research & Clinical Practice

Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failure

Article

Author: Sram, Krystof ; Lhotan, Jakub ; Jilich, David ; Sevela, Stanislav ; Rozsypal, Hanus

INTRODUCTION:

In patients with severe surgical and gastrointestinal complications, standard oral combination antiretroviral therapy (ARV) may be temporarily impossible. Long-acting cabotegravir/rilpivirine (CAB/RPV LA) is approved for virologically suppressed individuals pretreated with oral therapy, but data on its use in treatment-naïve, critically ill patients with absent enteral absorption are extremely limited.

CLINICAL PRESENTATION:

We report a 26-year-old male admitted with fulminant hypertriglyceridaemic necrotizing pancreatitis complicated by abdominal compartment syndrome, multiple laparotomies, open abdomen with enteric fistulae, short bowel syndrome type I, chronic intestinal failure requiring parenteral nutrition, portal vein thrombosis, and prolonged intensive care. HIV-1 infection was diagnosed early (HIV RNA 5,000 copies/mL; CD4+ 780 cells/µL). Within three months, HIV RNA rose to 320,000 copies/mL and CD4+ declined to 570 cells/µL. Given absent gastrointestinal passage, standard ARV was initially deferred, but rapid virological rebound necessitated urgent treatment. An off-label fully parenteral regimen was initiated: intravenous zidovudine (AZT) with intramuscular CAB/RPV LA. Therapy was well tolerated alongside surgery, parenteral nutrition, antimicrobials, and anticoagulation. HIV RNA decreased to <20 copies/mL within 65 days and remained suppressed, with CD4+ recovery. Intravenous AZT was discontinued after 35 days, and CAB/RPV LA continued as maintenance during recovery and home parenteral nutrition.

DISCUSSION:

Fully parenteral ARV, including CAB/RPV LA, may provide a safe and effective bridge to durable viral suppression in patients with absolute contraindications to oral therapy, warranting further evaluation.

01 Oct 2026·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

CABO–CHANCE study: A real-life world study of cabotegravir plus rilpivirine long-acting intramuscular in ART-experienced people with HIV

Article

Author: Romero, Alberto ; García-Aguilera, Maria ; Martinez, Onofre ; López, Teresa ; García-Ocaña, Paula ; Ruiz-Sancho, Andres ; Bernal, Enrique ; Moreno, Santiago ; López-Lirola, Ana ; Rivero, Antonio ; Hidalgo-Tenorio, Carmen ; Santos, Ignacio De Los ; Omar, Mohamed ; Sorni, Patricia ; Sanjoaquín, Isabel ; Garcia, Coral ; Blanco, Jose Ramon

BACKGROUND:

This study of people with HIV (PWH) receiving CAB + RPV LAI evaluated its effectiveness, safety, and impact on inflammatory markers, body fat/lean mass distributions, quality of life, sleep, health satisfaction, and stigma experience over 1 y.

METHODS:

A prospective, longitudinal, multicentre study was conducted in 15 hospitals and enrolled between June 2023 and January 2024. It included virologically suppressed PWH (HIV-1 RNA <50 c/mL for ≥6 months) switched from oral antiretroviral therapy to CAB + RPV LAI. Anthropometrics, CD4/CD8 counts, viral load, creatinine clearance, lipid levels, and inflammatory markers were recorded at baseline and 12, 28, 52 weeks. Patient-reported outcomes were gathered using the WHOQOL-HIV-BREF, HIV stigma scale for use in Spain, Pittsburgh Sleep Quality Index, and questionnaires on health satisfaction and adverse events. A subpopulation underwent to whole-body dual energy X-ray absorptiometer (DEXA).

RESULTS:

Among 269 PWH (mean age 45.6 y; 89.2% male), 240 completed 52-week follow-up, 14 (5.2%) were lost to follow-up, six (2.2%) withdrew consent, 5 (1.9%) were discontinued for adverse events, and one (0.4%) had virological failure (week 12). Snapshot effectiveness was 88.8% (intention-to-treat) and 97.5% (per-protocol). No oral bridging was required. CD4/CD8 ratio (P = 0.0001) and creatinine clearance (P = 0.0001) increased, d-dimer decreased at week 12 (P = 0.001), and BMI modestly increased (P = 0.046). No changes in total/regional fat or lean mass by DEXA (n = 56). Stigma (P = 0.029) and adverse events (P = 0.001) improved.

CONCLUSIONS:

In this real-world cohort, CAB + RPV LAI was highly effective and safe, was associated with a possible favourable immunologic response, a transient reduction in inflammation, and reduced perceived stigma over 1 y.

01 Sep 2026·IMMUNOLOGY

Long‐Acting Cabotegravir/Rilpivirine Reduces Immune‐Activation and ‐Senescence in People With HIV With CMV Co‐Infection

Article

Author: Mastroianni, Claudio Maria ; Pasquazzi, Caterina ; Dominelli, Federica ; Borgo, Cosmo Del ; Guardiani, Mariasilvia ; Tortellini, Eeva ; Zingaropoli, Maria Antonella ; Marocco, Raffaella ; Ciardi, Maria Rosa ; Carraro, Anna ; Lichtner, Miriam ; Vita, Serena ; Grimaldi, Alessandra ; Ansaldo, Lorenzo ; Mengoni, Fabio ; Turriziani, Ombretta ; Vullo, Vincenzo

ABSTRACT:

Despite the effectiveness of combined antiretroviral therapy (ART), HIV infection remains a chronic condition characterised by persistent inflammation and immune activation, likely associated with viral persistence and other factors such as cytomegalovirus (CMV) co‐infection. Long‐acting (LA) injectable formulations, a newer class of ART with improved and sustained bioavailability, may help modulate the HIV‐associated immunoinflammatory state. Therefore, we analysed dynamic changes in lymphoid immune‐activation and ‐senescence markers in people with HIV (PWH) switching to LA injectable cabotegravir and rilpivirine (CAB/RPV‐LA), compared with PWH who continued oral ART by choice. The relationship between CMV‐specific immune responses and phenotypic T‐cell alterations was also evaluated. T‐cell immune‐activation (CD38 + HLA‐DR+) and ‐senescence (CD28‐CD57+) were measured at baseline (T0), at 4 (T4), 28 (T28), 48 (T48) and at 72 (T72) weeks after switching to CAB/RPV‐LA. A control group (CG) of PWH (PWH‐CG) on daily oral ART was studied at T0 and at 48 weeks (T48). Furthermore, CMV‐specific cellular and humoral immune responses were assessed. Thirty‐seven PWH switching to CAB/RPV‐LA and nine PWH‐CG were enrolled. In PWH‐LA, total CD4 levels remained stable over time, while CD8 levels decreased significantly at T72 versus T0 and T4. In CG, an increasing CD4 and decreasing CD8 trend was observed. The CD4/CD8 ratio remained stable in both PWH‐LA and ‐CG and showed a nonsignificant increase at T48 in PWH‐CG. Immune‐activation decreased in PWH‐LA: CD4 activation levels were significantly lower at T48 and T72 versus earlier time points and CD8 activation was reduced at T72 versus T0 and T4. Immune‐senescence declined in both compartments, with a significant reduction in CD8 senescence at T28, T48 and T72 compared to earlier time‐points. Delta analysis confirmed a greater reduction in immune‐activation and ‐senescence in PWH‐LA compared to PWH‐CG. Regarding CMV immune response, anti‐CMV antibody levels remained stable with only a minor decline over time, whereas CMV‐specific T‐cell responses transiently increased at T28 before returning to baseline at T48 and T72. Switching to CAB/RPV‐LA is associated with reduced T‐cell activation and senescence, particularly in CD8 T‐cell, suggesting improved immune homeostasis beyond viral suppression alone. However, despite these promising immunological changes, CMV coinfection remains a key driver of residual immune dysfunction.

156

News (Medical) associated with Rilpivirine Hydrochloride

28 Aug 2026

·allsci.com

FDA approves Gilead's Bixlenvo to simplify complex HIV regimens

The US FDA has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single-tablet regimen (STR) for HIV-1 treatment in virologically suppressed adults — including, for the first time, those on complex multi-tablet regimens who could not previously use an STR. Gilead Sciences (Nasdaq: GILD) said the combination is the smallest oral STR and the first approved STR option for virologically suppressed patients on complex regimens who are unable to use existing STRs because of factors including historical resistance or tolerability. Bixlenvo is indicated as a complete regimen for adults with HIV-1 RNA below 50 copies per mL on a stable antiretroviral regimen, with no known or suspected resistance to either component. Initiation requires a two-day loading period with Sunlenca (lenacapavir) co-administered alongside Bixlenvo, after which Bixlenvo is taken alone once daily. Contraindications include co-administration with dofetilide and strong CYP3A inducers. Approval rested on two Phase III trials — ARTISTRY-1 (NCT05502341) and ARTISTRY-2 (NCT06333808) — both evaluating virologic suppression maintenance at Week 48 after switching to Bixlenvo. ARTISTRY-1 enrolled a notably treatment-experienced population: median age 60 years, median 28 years on antiretroviral therapy, 67% with nucleoside reverse transcriptase inhibitor (NRTI) resistance, and 81% on complex regimens due to resistance. Both trials reported comparable efficacy to prior regimens and no new safety signals; the most common adverse reactions were headache (4%), nausea (3%), and diarrhea (2%). ARTISTRY-1 results were published in The Lancet and ARTISTRY-2 in Lancet HIV. Bictegravir is an integrase strand transfer inhibitor (INSTI) that blocks insertion of viral cDNA into the host genome. Lenacapavir, a first-in-class capsid inhibitor also marketed as Sunlenca, disrupts capsid-dependent processes across multiple stages of the HIV lifecycle — nuclear import, uncoating, and virion assembly — with no cross-resistance to other approved antiretroviral classes. The approval adds another option to an increasingly competitive HIV switch market that includes ViiV Healthcare's Dovato (dolutegravir/lamivudine), long-acting injectable Cabenuva (cabotegravir/rilpivirine), and Merck's recently approved Idvynso (doravirine/islatravir). Bixlenvo is differentiated by its ability to simplify treatment for some heavily treatment-experienced patients currently requiring complex multi-tablet regimens. Spot something wrong? Report an issue with this article

Phase 3Drug ApprovalClinical ResultClinical StudyOligonucleotide

27 Aug 2026

·www.pharmaceutical-technology.com

ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy

The studies indicated that dolutegravir reached therapeutic levels in neonates and showed a safety profile similar to older patients. Credit: Gorodenkoff/Shutterstock.com. The US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay PD (dolutegravir), for use with other antiretroviral agents in paediatric patients with human immunodeficiency virus type 1 (HIV-1) who weigh at least 2kg. The therapy is indicated for children who are either new to treatment or have prior experience with antiretroviral therapies but have not been treated with integrase strand transfer inhibitors (INSTIs). ViiV Healthcare is a global HIV specialist company, majority owned by GSK, with Shionogi as a shareholder. Tivicay PD’s approval follows a Priority Review by the FDA. The decision is backed by data from the International Maternal Paediatric Adolescent AIDS Clinical Trials (IMPAACT) 2023 clinical study, funded by the National Institutes of Health (NIH), as well as additional paediatric pharmacokinetic modelling. The studies indicated that dolutegravir, described as a second-generation INSTI, reached therapeutic levels in term neonates and demonstrated a safety profile similar to that of older children and adults taking the drug. ViiV Healthcare chief medical officer Jean van Wyk said: “Today’s approval of Tivicay PD expands the options available for paediatric HIV care, giving families and clinicians in the US greater choice from the very beginning of life. “For ViiV Healthcare, it reflects our commitment to bringing INSTI-based innovation to children and addressing persistent gaps in HIV care. “This progress has been made possible through vital collaboration with the HIV community, united by a shared focus on ensuring children living with HIV are not left behind.” Tivicay and Tivicay PD both contain dolutegravir, which is designed to inhibit HIV integrase and block a critical step in the virus’ replication cycle. IMPAACT, the clinical research network behind the pivotal trial, brings together investigators and partners worldwide. It studies interventions for HIV and related conditions across different populations. The NIH, which supported the research, is the primary US federal agency for medical investigation and part of the Department of Health and Human Services. In February 2025, the European Commission authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus Rekambys (rilpivirine long-acting injections) from Johnson & Johnson for treating adolescents with HIV-1.

Drug ApprovalClinical StudyPriority Review

04 Aug 2026

·www.businesswire.com

ViiV Healthcare Launches “Do It For Future You” Campaign Inspiring People to Prioritize Their Sexual Health and Future

DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, announced the launch of “Do It For Future You,” a new multichannel campaign designed to inspire individuals to take control of their health today to better safeguard their future. The campaign encourages discussions between individuals and their health providers about long-acting injectable HIV prevention and treatment options. The campaign uses one clear message: the choices you make today shape your tomorrow. Our goal with ‘Do It For Future You’ is to help people see that the health decisions they make now shape the life they are building, regardless of their HIV status. Despite scientific progress transforming HIV from a debilitating and fatal illness into a manageable chronic condition, the epidemic persists, with more than 39,000 U.S. diagnoses annually.1 Critical gaps in connection to care remain: only about 25% of people who could benefit from pre-exposure prophylaxis (PrEP), a medication that can prevent HIV in people who are HIV-negative, are currently taking it,2 and nearly a third of people living with HIV in the U.S. (31%) have not yet achieved viral suppression, which threatens their health and allows for further transmission of HIV.1 Long-acting injectable (LAI) options could help to close these gaps and have been shown to improve adherence and persistence in HIV medicine, leading to continuous viral suppression or protection from HIV. This not only helps to improve long-term individual health outcomes but also helps to reduce transmission, contributing to protecting broader public health.3,4,5,6,7,8,9,10,11,12,13,14,15 “Do It For Future You” is brought to life through a series of interconnected, relatable stories, anchored by a new website (ForFutureU.com). The campaign's hero film calls on individuals to prioritize their wellness and take action: “Do it for the you who’s still becoming... The future doesn’t begin someday. It begins right now. With what you do next. With a conversation. A question. A choice you can feel good about.” “Our goal with ‘Do It For Future You’ is to help people see that the health decisions they make now shape the life they are building, regardless of their HIV status,” said Bithiah Lafontant, Head of Enterprise Communications at ViiV Healthcare. “We believe long-acting injectables are key to building healthy futures because having different treatment and prevention options can help ensure that no one is left behind. For individuals who may find a daily routine challenging, or where persistent stigma creates a barrier to care, long-acting options offer another way to stay consistent, making a thriving, healthy future feel truly within reach.” “As a trusted community partner and leader of innovation in long-acting HIV prevention and treatment, ViiV Healthcare believes that having a choice in your medicine is essential,” Lafontant added. “By expanding the options available, people can manage their health in a way that actually fits their lives. Whether it’s starting PrEP, beginning treatment, or reconnecting to care, every one of those decisions is a powerful act of self-care and a confident step towards a promising future.” With more options available than ever before, ViiV Healthcare wants people to walk into their doctor’s appointments prepared with the right questions about dosing, administration, and what to expect from their medicine. Lafontant continued, “We want people to understand the simple message of this campaign: Your future belongs to you, not HIV. Take control of your sexual health today by asking the right questions and visiting ForFutureU.com to explore resources for talking with your health provider about long-acting injectable HIV prevention and treatment options, and make the choice that best fits your life.” About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q2 Results for 2026. References: 1. Centers for Disease Control and Prevention. National HIV prevention and care objectives, 2026. Published 2026. Accessed. https://www-cdc-gov.libproxy1.nus.edu.sg/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2026.html. 2. Centers for Disease Control and Prevention. Core indicators for monitoring the Zeroing In on HIV (ZIH) initiative. HIV Surveillance Data Tables. 2023;4(1). Published August 2023. https://www-cdc-gov.libproxy1.nus.edu.sg/hiv/library/reports/surveillance-data-tables/vol-4-no-1/index.html. 3. Hickey MD, Gistand N, Grochowski J, Mayorga-Munoz F, Imbert E, Szumowski JD, Oskarsson J, Shiels M, Dilworth S, Appa A, Havlir DV, Gandhi M, Christopoulos K. Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia. Clin Infect Dis. 2025 Apr 30;80(4):864-870. 4. Garris C, et al. Real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the U.S.: the ABOVE Study. Open Forum Infectious Diseases 2023 (10; Suppl. 2):ofad500.055, https://doi-org.libproxy1.nus.edu.sg/10.1093/ofid/ofad500.055. 5. Christopoulos KA, et al. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clin Infect Dis. 2023 Feb 8;76(3):e6-e651. 6. Smith GHR, et al. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. 7. Orkin C, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021 Apr;8(4):e185-e196. 8. Gandhi M, et al. Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV. Ann Intern Med 2023;176(7):969-974. 9. Jonsson-Oldenbüttel C, et al. 12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study. 25th International AIDS Conference; July 22–26, 2024; Munich, Germany: Poster TUPEB095. https://viivexchange.com/content/dam/cf-viiv/viivexchange/medical/pdf/aids-2024-jonsson-oldenb%C3%BCttel-carlos-12m-clin-effect-tupeb095-final-disc.pdf. 10. Hsu RK, et al. Real-world effectiveness of cabotegravir + rilpivirine vs standard of care oral regimens in the U.S. CROI 2024, Denver, CO, USA: Poster 623. https://www.croiconference.org/wp-content/uploads/sites/2/posters/2024/623.pdf. 11. Eron JR, et al. Real-world utilization of cabotegravir + rilpivirine in the U.S.: data from Trio health cohort. CROI 2024, Denver, CO, USA: Poster 625. https://www.croiconference.org/wp-content/uploads/sites/2/posters/2024/625.pdf. 12. Dandachi D, et al. Clinical outcomes and perspectives of people with human immunodeficiency virus type 1 twelve months after initiation of long-acting cabotegravir and rilpivirine in an observational real-world U.S. study (BEYOND). Open Forum Infect Dis. 2025 Apr 19;12(5):ofaf220. 13. Hastie E, Hill L, Bamford L, Karim A, Martin TCS. Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy. Clin Infect Dis. 2025 Mar 17:ciaf120. doi: 10.1093/cid/ciaf120. 14. Parker B, et al. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study. PLoS One. 2021;16(2):e02955. 15. Barda B, et al. Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis. HIV Med 2025;26(7):993-1003.

Phase 3Clinical Result

100 Deals associated with Rilpivirine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D09720 D09958	Rilpivirine Hydrochloride	J05AG05	DB08864

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Janssen Products LP	20 May 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	United States	Janssen Scientific Affairs LLC	09 Apr 2009
Hepatitis	Phase 1	United States	ViiV Healthcare Ltd.	01 Nov 2011
Hepatitis C	Phase 1	-	Tibotec Pharmaceuticals	01 Nov 2010
Contraception	Phase 1	-	Tibotec Pharmaceuticals	01 Jul 2008
Contraception Behavior	Phase 1	-	Tibotec Pharmaceuticals	01 Jul 2008
Acquired Immunodeficiency Syndrome	Phase 1	-	Tibotec Pharmaceuticals	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2026	Not Applicable	HIV Infections	111	LAI CAB/RPV (HIV)	ntuunzxmfr(awrkitznte) = gaavesrysf sqniypriib (voeygnafuy ) View more	Positive	26 Jul 2026
OPERA Cohort (IAS2026)	Not Applicable	HIV Infections	583	Cabotegravir + rilpivirine long-acting (CAB+RPV LA) (BMI <30 kg/m²)	lwkxzanyhh(ammvfrfthi) = gslnvvtmet nbwrdqiftb (gpujrfmkfv ) View more	Positive	26 Jul 2026
				Cabotegravir + rilpivirine long-acting (CAB+RPV LA) (BMI =30 to <40 kg/m²)	lwkxzanyhh(ammvfrfthi) = bwvvjlouku nbwrdqiftb (gpujrfmkfv ) View more
IAS2026	Not Applicable	Cognitive Dysfunction	22	LAI CAB/RPV	ykcxrtrjnv(exnxaeapwu) = three participants discontinued LAI CAB/RPV, all due to injection-site pain wjebtnmdht (wcxdxclrim ) View more	Positive	26 Jul 2026
IAS2026	Not Applicable	HIV Infections	66	Long-acting cabotegravir plus rilpivirine (CAB+RPV LA) (Viral suppression + HIV)	tuoatlujyd(lwcvrgduwt) = Drug-related adverse events were infrequent. Injection-site pain was mostly mild. xmkgxnfiqy (jtwbvergpk ) View more	Positive	26 Jul 2026
OPERA (IAS2026)	Not Applicable	HIV Infections	7,954	cabotegravir + rilpivirine long-acting (CAB+RPV LA)	invdqxrxnm(wxuyoqqcja) = rjhpmrtnad apjdwktoai (njdyykwtgq ) View more	Positive	26 Jul 2026
				Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)	invdqxrxnm(wxuyoqqcja) = mqecilgims apjdwktoai (njdyykwtgq ) View more
IAS2026	Not Applicable	HIV Infections	51	cabotegravir+rilpivirine	nlchlwjrcs(ofmdwkecgs) = mfvmoyhqdq vrsrdygslr (nygnzmcrey ) View more	Negative	26 Jul 2026
IMPALA (IAS2026)	Phase 3	HIV Infections	540	LAI CAB+RPV	wtdyvuiesu(rzwltymqse): AMD = 0.52, P-Value = 0.336 View more	Positive	26 Jul 2026
				DTG-based ART
IAS2026	Not Applicable	HIV Infections	343	Switched from stable oral tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART)	wqimjxhagp(kcioemgxlj) = rpzwwnstst ztslcbqqgx (nyujotvnue ) View more	Positive	26 Jul 2026
				Switched from oral TAF-free ART	wqimjxhagp(kcioemgxlj) = ypuqhdaoka ztslcbqqgx (nyujotvnue ) View more
NCT03635788 (LATITUDE, Pubmed) Manual	Phase 3	HIV Infections	306	Cabotegravir+rilpivirine	iakoscntfz(vcqiscuuwj) = hzvzutknxr vdcoswfjaz (usqqfttvaz ) View more	Positive	26 Feb 2026
				Standard care	iakoscntfz(vcqiscuuwj) = nglnosohkp vdcoswfjaz (usqqfttvaz ) View more
NCT04542070 (SOLAR, Pubmed \| J Infect Chemother)	Phase 3	HIV Infections	396	Cabotegravir+rilpivirine (CAB+RPV) LA Q2M with a 1-month optional once-daily OLI of CABRPV) LA Q2M with a 1-month optional once-daily OLI of CAB+RPV	ryncwbsers(yrhbdlfhoh) = unqhkunrvm vzafizoaxw (qmatgfknnk ) View more	Positive	01 Dec 2025
				Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	ryncwbsers(yrhbdlfhoh) = ncwpdvoktm vzafizoaxw (qmatgfknnk ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis